AXSOME THERAPEUTICS, INC. Operating Lease, Expense
AXSOME THERAPEUTICS, INC. (AXSM) reported Operating Lease, Expense of $2.20 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-02-23
- AXSOME THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $2.20M, a 69.23% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $1.30M, a 8.33% increase from fiscal 2021.
- AXSOME THERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $1.20M, a 37.89% increase from fiscal 2020.
- AXSOME THERAPEUTICS, INC. operating lease, expense for fiscal 2020 was $870.27K, a 79.24% increase from fiscal 2019.
| Period end | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|
| 2023-12-31 | $2.20M 10-K · filed 2024-02-23 | |
| 2022-12-31 | $1.30M 10-K · filed 2024-02-23 | $1.26M 10-K · filed 2023-02-28 |
| 2021-12-31 | $1.20M 10-K · filed 2024-02-23 | $1.18M 10-K · filed 2022-03-01 |
| 2020-12-31 | $870.27K 10-K · filed 2023-02-28 | |
| 2019-12-31 | $485.55K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |